Hubbry Logo
MMP2MMP2Main
Open search
MMP2
Community hub
MMP2
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
MMP2
MMP2
MMP2
View on Wikipedia
from Wikipedia

mmp2
Identifiers
Aliasesmatrix metallopeptidase 2wu:fa99h12wu:fk89d01
External IDsMGI: 97009; HomoloGene: 3329; GeneCards: [1]; OMA:- orthologs
Orthologs
SpeciesHumanMouse
Entrez

337179

17390

Ensembl

ENSDARG00000017676

ENSMUSG00000031740

UniProt

Q7SZM5

P33434

RefSeq (mRNA)

NM_198067

NM_008610

RefSeq (protein)

NP_932333

NP_032636

Location (UCSC)Chr 7: 35.41 – 35.43 MbChr 8: 93.55 – 93.58 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

72 kDa type IV collagenase also known as matrix metalloproteinase-2 (MMP-2) and gelatinase A is an enzyme that in humans is encoded by the MMP2 gene.[4] The MMP2 gene is located on chromosome 16 at position 12.2.[5]

Function

[edit]

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. This gene encodes an enzyme which degrades type IV collagen, the major structural component of basement membranes. The enzyme plays a role in endometrial menstrual breakdown, regulation of vascularization and the inflammatory response.[6]

Activation

[edit]

Activation of MMP-2 requires proteolytic processing. A complex of membrane type 1 MMP (MT1-MMP/MMP14) and tissue inhibitor of metalloproteinase 2 recruits pro-MMP 2 from the extracellular milieu to the cell surface. Activation then requires an active molecule of MT1-MMP and auto catalytic cleavage. Clustering of integrin chains promotes activation of MMP-2. Another factor that will support the activation of MMP-2 is cell-cell clustering. A wild-type activated leukocyte cell adhesion molecule (ALCAM) is also required to activate MMP-2.

Clinical significance

[edit]

Mutations in the MMP2 gene are associated with Torg-Winchester syndrome, multicentric osteolysis, arthritis syndrome,[7][8] and possibly keloids.

Role of MMP-2 in chronic disease

[edit]

Activity of MMP-2 relative to the other gelatinase (MMP-9) has been associated with severity of chronic airway diseases including Idiopathic interstitial pneumonia and Bronchiectasis. In idiopathic interstitial pneumonia, MMP-2 activity was elevated in patients with the less severe disease phenotype which is more responsive and reversible with corticosteroid therapy.[9] In non-cystic fibrosis bronchiectasis, MMP-2 concentration was elevated in patients with Haemophilus influenzae airway infection compared to Pseudomonas aeruginosa airway infection.[10] Bronchiectasis patients with P. aeruginosa infection have a more rapid decline in lung function.[11] Disease-causing mutations in the MMP2 gene cause a rare type of skeletal dysplasia Multicentric Osteolysis, Nodulosis, and Arthropathy syndrome. Abnormal mutations cause defective collagen remodelling. The disease manifestations include bone destruction especially of the wrists and tarsus, generalized osteoporosis and joint stiffness and eventually destruction.[12][8]

Altered expression and activity levels of MMPs have been strongly implicated in the progression and metastasis of many forms of cancer. Increased MMP-2 activity has also been linked with a poor prognosis in multiple forms of cancer including colorectal, melanoma, breast, lung, ovarian, and prostate.[13] Furthermore, changes in MMP-2 activity can come from alterations in levels of transcription, MMP secretion, MMP activation, or MMP inhibition. MMP production in many cancers may be upregulated in surrounding stromal tissue rather than simply in the tumor lesion. For instance, Mook, et al. showed that MMP-2 mRNA levels are strikingly similar between metastatic and non-metastatic lesions in colorectal cancer, but metastatic cases are correlated with higher levels of MMP-2 mRNA in surrounding healthy tissue.[14] For this reason, it is difficult to fully understand the complex role of MMPs in cancer progression.

Role in cancer cell invasion

[edit]

One of the major implications of MMPs in cancer progression is their role in ECM degradation, which allows cancer cells to migrate out of the primary tumor to form metastases. More specifically, MMP-2 (along with MMP-9) is capable of degrading type IV collagen, the most abundant component of the basement membrane. The basement membrane is important for maintaining tissue organization, providing structural support for cells, and influencing cell signaling and polarity. Degradation of the basement membrane is an essential step for the metastatic progression of most cancers.[14]

Cancer cell invasion, ECM degradation, and metastasis are highly linked with the presence of invadopodia, protrusive and adhesive structures on cancer cells. Invadopodia have been shown to concentrate MMPs (including MT1-MMP, MMP-2, and MMP-9) for localized release and activation.[15] Furthermore, degradation products of MMP activity may further promote invadopodia formation and MMP activity.[16] Finally, MMP-2 and several other MMPs have been shown to proteolytically activate TGF-β, which has been shown to promote epithelial mesenchymal transition (EMT), a key process involved in cancer metastasis.[17]

Role in cell signaling

[edit]

MMP degradation of the ECM affects cellular behavior through changes in integrin-cell binding, by releasing growth factors harbored by the ECM, by generating ECM degradation products, and by revealing cryptic binding sites in ECM molecules.[18] For instance, MMP-2 degradation of collagen type I can reveal a previously inaccessible cryptic binding site that binds with the αvβ3 integrin expressed by human melanoma cells. Signaling through this integrin is necessary for melanoma cell viability and growth in a collagen matrix and can potentially rescue the cells from apoptosis.[19] As another example, cleavage of laminin-5, a component of the basement membrane, by MMP-2 has been shown to reveal a cryptic site inducing migration of breast epithelial cells.[20]

More generally, by degrading the ECM, MMPs release growth factors that were previously bound to the ECM, allowing them to bind with cell receptors and influence cell signaling. Furthermore, many MMPs also activate other proMMPs along with growth factors.[18] MMP-2 has also been shown to cleave other non-ECM substrates including growth factors such as TGF-β, FGF receptor-1, proTNF, IL-1β and various chemokines.[21] For instance, MMP-2 has been implicated, along with MMP-9 in cleaving latent TGF-β, which has complex interactions with cancer cells. TGF-β generally plays a role in maintaining tissue homeostasis and preventing tumor progression. However, genetically unstable cancer cells can often evade regulation by TGF-β by altering TGF-β receptors in downstream signaling processes. Furthermore, expression of TGF-β is also correlated with immune tolerance and may help shield cancer cells from immune regulation.[22]

Role in neovascularization and lymphangiogenesis

[edit]

MMP-2 also plays an important role in the formation of new blood vessels within tumors, a process known as angiogenesis. This process is essential for tumor progression, because as tumors grow they need increasing supplies of oxygen and nutrients. Localized MMP-2 activity plays an important role in endothelial cell migration, a key feature of angiogenesis. Additionally, MMP-9 and other MMPs have been suggested to also play a complex, indirect role in angiogenesis by promoting VEGF mobilization and generating antiangiogenic factors.[14]

For instance, when studying carcinogenesis of pancreatic islets in transgenic mice, Bergers et al. showed that MMP-2 and MMP-9 were upregulated in angiogenic lesions and that the upregulation of these MMPs triggered the release of bioactive VEGF, a potent stimulator of angiogenesis. Additionally, the group determined that MMP-2 knockout mice showed decreased rates of tumor growth relative to tumor growth rates in wild type mice.[23] Furthermore, increased expression and activity of MMP-2 has been tied to increased vascularization of lung carcinoma metastases in the central nervous system, which likely increases survival rate of these metastases.[24]

Finally, MMP-2 has been also shown to drive lymphangiogenesis, which is often excessive in tumor environments and can provide a route of metastasis for cancer cells. Detry, et al. showed that knocking down mmp2 in zebrafish prevented the formation of lymphatic vessels without altering angiogenesis, while MMP-2 inhibition slowed the migration of lymphatic endothelial cells and altered the morphology of new vessels.[14] These results suggest that MMP-2 may alter tumor viability and invasion by regulating lymphangiogenesis in addition to angiogenesis.

Inhibition of MMP-2 as cancer therapy

[edit]

Clinical trials for cancer therapies using MMP inhibitors have yielded generally unsuccessful results. These poor results are likely due to the fact that MMPs play complex roles in tissue formation and cancer progression, and indeed many MMPs have both pro and anti-tumorogenic properties. Furthermore, most clinical studies involve advanced stages of cancer, where MMP inhibitors are not particularly effective. Finally, there are no reliable biomarkers available for assessing the efficacy of MMP inhibitors and MMPs are not directly cytotoxic (so they do not cause tumor shrinkage), so it is difficult for researchers to determine whether the inhibitors have successfully reached their targets.[13]

However, initial clinical trials using broad spectrum MMP inhibitors did show some positive results. Phase I clinical trials showed that MMP inhibitors are generally safe with minimal adverse side effects. Additionally, trials with marimastat did show a slight increase in survival of patients with gastric or pancreatic cancer.[13]

Various research groups have already suggested many strategies for improving the effectiveness of MMP inhibitors in cancer treatment. First, highly specific MMP inhibitors could be used to target the functions of specific MMPs, which should allow doctors to increase the treatment dosage while minimizing adverse side effects. MMP inhibitors could also be administered along with cytotoxic agents or other proteinase inhibitors. Finally, MMP inhibitors could be used during earlier stages of cancer to prevent invasion and metastasis.[13]

Additionally, the overexpression of MMPs in tumors can potentially be leveraged to direct the release of chemotherapeutic agents specifically to tumor sites. For example, cytotoxic agents or siRNA could be encapsulated in liposomes or viral vectors that become activated only upon proteolytic cleavage by a target MMP. Moreover, the tumor-targeting characteristics of MMP inhibitors provide a promising strategy for identifying small tumors. Researchers could link MMP inhibitors to imaging agents to facilitate the detection of tumors before they spread. Though initial trials yielded disappointing results, MMP inhibitors offer significant potential for improving cancer treatment by slowing the process of cancer cell invasion and metastasis.[13]

Interactions

[edit]

MMP2 has been shown to interact with:

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

MMP2

View on Grokipedia
from Grokipedia
Matrix metallopeptidase 2 (MMP2), also known as 72 kDa type IV collagenase or , is a zinc-dependent encoded by the on 16q12.2 in humans. This enzyme belongs to the matrix metalloproteinase (MMP) family and primarily functions to cleave components of the (ECM), such as type IV and V collagens, , , and , thereby regulating tissue remodeling and . MMP2 is synthesized as a proenzyme () with a molecular weight of approximately 72 kDa, featuring a pro-domain, a catalytic domain containing three fibronectin type II repeats for substrate binding, a hinge region, and a hemopexin-like domain that influences substrate specificity and inhibitor interactions. Its activity is tightly regulated by tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP2, which forms a complex with MMP2 to modulate its activation and prevent excessive proteolysis. In physiological contexts, MMP2 plays essential roles in diverse processes, including embryonic development, , , , and endometrial cyclic breakdown during the . It is broadly expressed across tissues, with particularly high levels in the and urinary , and contributes to vascular homeostasis, immune cell infiltration, and nervous system plasticity by facilitating ECM degradation and cell signaling. Dysregulation of MMP2 is implicated in numerous pathologies, where its overexpression often promotes pathological remodeling. In cancer, elevated MMP2 activity facilitates tumor invasion and by degrading basement membranes, correlating with poor prognosis in , , and other malignancies. mutations in MMP2, such as frameshifts or missense variants, such as R101H in the pro-domain and E404K in the catalytic domain, cause rare autosomal recessive disorders like Winchester syndrome and nodulosis-arthropathy-osteolysis (NAO) syndrome, characterized by multicentric osteolysis, joint destruction, and nodular skin lesions due to impaired ECM turnover. Additionally, MMP2 contributes to cardiovascular diseases like and Takayasu arteritis through vascular remodeling, as well as inflammatory conditions including and . Ongoing explores MMP2 as a therapeutic target, with inhibitors showing potential in limiting and tissue damage, though challenges remain in balancing its beneficial and detrimental functions.

Molecular Biology

Gene and Expression

The human MMP2 gene, encoding matrix metalloproteinase 2 (also known as gelatinase A), is located on the long arm of chromosome 16 at cytogenetic band q12.2. It spans approximately 17 kb of genomic DNA and consists of 13 exons ranging from 110 to 901 bp in length, separated by 12 introns. The gene structure supports the production of a preproenzyme precursor that undergoes processing to yield the mature protein. Alternative splicing of MMP2 transcripts generates multiple isoforms, including variants that may influence protein localization or function, though the canonical transcript predominates in most tissues. Transcriptional regulation of MMP2 is tightly controlled by key factors such as AP-1, , and Sp1, which bind to promoter elements in response to extracellular signals. Cytokines like TNF-α and IL-1β activate and AP-1 pathways to upregulate MMP2 expression in stromal and inflammatory cells, promoting matrix remodeling during . Growth factors such as TGF-β modulate Sp1 binding, often exerting biphasic effects: low doses induce MMP2 transcription via Smad signaling, while higher concentrations suppress it through inhibitory interactions. These mechanisms ensure context-dependent expression, linking MMP2 to processes like and tissue repair. MMP2 exhibits broad tissue expression, with highest mRNA levels in the gall bladder and urinary bladder, and notable protein expression in , , and fibroblasts, where it supports turnover. Expression is low or absent in most epithelia but can be robustly induced in endothelial cells and macrophages by stimuli such as hypoxia or inflammatory cytokines, facilitating and immune . Post-transcriptional regulation further fine-tunes MMP2 levels; for instance, miR-145 directly targets the 3' untranslated region of MMP2 mRNA, suppressing and reducing protein abundance in vascular cells. miR-143, often co-expressed with miR-145, contributes to related regulatory networks. The MMP2 gene is highly conserved across mammals, sharing over 90% sequence identity with its mouse ortholog Mmp2, enabling functional studies in models. Knockout of Mmp2 in results in viable animals with subtle developmental phenotypes, including reduced embryo implantation sites due to impaired trophoblast invasion and altered vascular patterning in tissues like the and . These defects highlight MMP2's essential role in early reproductive and vascular development without causing outright embryonic lethality. The gene also informs downstream protein domains, such as the hemopexin-like repeats derived from specific exons.

Protein Structure

Matrix metalloproteinase-2 (MMP2), also known as gelatinase A, is synthesized as a 72 kDa proenzyme consisting of 660 amino acids. The protein features a modular domain organization typical of the MMP family, beginning with a signal peptide spanning amino acids 1-24, which directs the nascent polypeptide to the secretory pathway for extracellular release. Following the signal peptide is the prodomain (amino acids 25-111), which maintains enzyme latency through a conserved PRCXV motif where the cysteine residue coordinates with the catalytic zinc ion to prevent premature activation. The catalytic domain (amino acids 112-302) houses the active site, including three histidine residues that bind the essential zinc ion and the conserved HEXXH motif critical for peptidolytic activity. A short hinge region (amino acids 303-309) connects the catalytic domain to the C-terminal hemopexin-like domain (amino acids 310-660), which adopts a four-bladed β-propeller fold and contributes to substrate specificity by modulating interactions with extracellular matrix components and inhibitors. MMP2 undergoes post-translational modifications that influence its biophysical properties and secretion. It is secreted as a soluble with N-linked sites at Asn-127 and Asn-189 within the catalytic domain, which enhance protein stability, facilitate proper folding, and promote efficient cellular secretion. These modifications contribute to the protein's acidic (pI) of approximately 5.5, enabling its solubility in physiological fluids. The remains stable at neutral pH but exhibits optimal enzymatic activity under slightly acidic conditions, reflecting its role in dynamic extracellular environments such as remodeling tissues. Unlike most MMPs, MMP2 is classified as a gelatinase due to the insertion of three consecutive type II modules within its catalytic domain, which confer specificity for binding and degrading denatured collagens (gelatins) and native . These modules, absent in archetypal MMPs like MMP-1 or MMP-3, enable MMP2 to unwind and cleave triple-helical collagens more effectively, distinguishing its substrate repertoire. Additionally, the hemopexin-like domain supports homodimerization, as evidenced by biochemical studies showing intermolecular interactions that may regulate localization and activity on cell surfaces. This dimerization potential underscores MMP2's capacity for cooperative functions in matrix degradation.

Enzymology

Catalytic Function

Matrix metalloproteinase-2 (MMP2), also known as gelatinase A, functions as a zinc-dependent that primarily cleaves (ECM) components, with particular efficiency against (denatured ) and native . It hydrolyzes these substrates at specific Gly-Leu or Gly-Ile bonds within the α-chains, facilitating the degradation of structures.34375-5/fulltext) MMP2 exhibits a broad substrate repertoire beyond collagens, including ECM proteins such as , , and , as well as non-matrix targets like aggrecan and myelin basic protein, underscoring its role in diverse proteolytic processes. The catalytic mechanism of MMP2 relies on a conserved where a catalytic (Zn²⁺) is coordinated by three residues (His403, His407, and His413), forming a trigonal pyramidal that polarizes a bound . This acts as a , deprotonated by the adjacent glutamate residue (Glu404) serving as a general base, to initiate nucleophilic attack on the carbonyl carbon in a Zn-OH⁻ mediated pathway. The reaction proceeds via a tetrahedral intermediate, leading to scissile bond cleavage and product release, consistent with the metzincin superfamily mechanism. MMP2 operates optimally at a neutral to slightly alkaline of 7.5–8.5, retaining substantial activity (about 50%) even at 6.5, which aligns with physiological conditions in extracellular environments. Kinetic analyses reveal MMP2's high efficiency for ECM substrates, with a Michaelis constant (Km) for degradation in the range of 10–50 μg/mL and a catalytic efficiency (kcat/Km) for approaching 105 M-1 s-1, enabling rapid pericellular . This localized activity is enhanced by MMP2's association with cell surfaces through binding to (e.g., αvβ3) or , positioning the enzyme for targeted ECM remodeling near invading or migrating cells.

Activation Mechanism

Matrix metalloproteinase 2 (MMP2), also known as gelatinase A, is synthesized as an inactive proenzyme (pro-MMP2) to prevent uncontrolled proteolysis. The latency of pro-MMP2 is maintained by a prodomain that employs a "cysteine switch" mechanism, wherein the conserved cysteine residue at position 102 (Cys-102) coordinates with the catalytic zinc ion (Zn²⁺) in the active site, blocking substrate access and inhibiting autocatalytic activation. This interaction ensures that MMP2 remains dormant until specific proteolytic signals are received. The primary physiological activation of pro-MMP2 occurs on the cell surface via membrane-type 1 (MT1-MMP, or MMP14), which initiates cleavage at the bond between 94 and 95 (Ala⁹⁴-Leu⁹⁵) in the prodomain. This initial cleavage exposes a new site, leading to subsequent autolytic removal of the prodomain and generation of the active enzyme. This process is tightly regulated by tissue inhibitor of metalloproteinases 2 (TIMP-2), which forms a ternary complex with MT1-MMP and pro-MMP2; the N-terminal domain of TIMP-2 binds to the of MT1-MMP, while the C-terminal domain recruits pro-MMP2, facilitating localized and controlled activation to avoid widespread tissue damage. Alternative activation pathways exist, particularly or under specific conditions. Serine proteases such as and can cleave pro-MMP2 at sites within the prodomain, converting it to an intermediate form that undergoes further . Chemical agents like 4-aminophenylmercuric (APMA) disrupt the cysteine switch by mercurial modification of Cys-102, enabling rapid in experimental settings. Under physiological conditions, the activation kinetics of pro-MMP2 by the exhibit a of approximately 30-60 minutes, resulting in the production of active at 66 (after initial cleavage) and further to 59 via additional . In pathological contexts, such as , dysregulation can occur through overactivation by , which directly cleaves pro-MMP2 and contributes to excessive matrix degradation in conditions like tumor invasion and chronic inflammatory diseases.

Physiological Roles

Tissue Remodeling and Wound Healing

Matrix metalloproteinase-2 (MMP2) is essential for the controlled turnover of the (ECM) in healthy tissues, where it balances the synthesis and degradation of ECM components such as and . In , MMP2 facilitates dermal remodeling by degrading type I and IV collagens, maintaining structural integrity and flexibility. Similarly, in and , MMP2 contributes to the of mineralized and cartilaginous matrices by cleaving non-collagenous proteins and supporting osteocyte-osteoblast interactions, ensuring adaptive responses to mechanical stress without excessive tissue breakdown. During wound healing, MMP2 plays a key role in the proliferative phase by promoting migration across the provisional matrix and facilitating formation through targeted degradation of the . This proteolytic activity allows epithelial cells to advance and establish new tissue layers, with MMP2 expression peaking around days 3-7 post-injury in models of cutaneous wounds, coinciding with maximal reepithelialization rates. In the , MMP2 aids uterine involution by degrading the decidual matrix and excess ECM accumulated during , restoring the to its pre-gravid state; studies in mice show elevated MMP2 activity in the and during this process, underscoring its necessity for timely resorption. Recent studies in mice demonstrate that MMP2 deficiency leads to defective parturition and high rates of dystocia, highlighting its essential role in cervical and myometrial ECM remodeling during labor. In , MMP2 supports osteoclast-mediated breakdown and matrix resorption during repair, enabling the transition from formation to mature restructuring. MMP2 is expressed by osteoclasts and osteoblasts at the bone-matrix interface, where it cleaves fibrillar collagens and activates signaling pathways that coordinate resorption with subsequent deposition, as evidenced by delayed remodeling phases in MMP2-deficient models of tibial s. Homeostatic regulation of MMP2 maintains low basal activity through tight control by tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP-2, which forms complexes with pro-MMP2 to prevent untimely and preserve ECM integrity across tissues. This inhibitor-enzyme balance is crucial for avoiding pathological degradation while permitting physiological adaptations.

Development and Angiogenesis

Matrix metalloproteinase-2 (MMP2) plays a pivotal role in embryonic development, particularly in facilitating invasion and implantation. During early embryogenesis, MMP2 degrades components of the (ECM), enabling cells to penetrate the endometrial stroma and establish maternal-fetal connections essential for successful implantation. studies using mouse trophoblastic cells demonstrate that MMP2 treatment enhances cell spreading and invasion, underscoring its direct contribution to this process. Although MMP2-null (MMP2^{-/-}) mice are viable and fertile, recent studies indicate reproductive impairments such as defective parturition and dystocia due to altered uterine remodeling. In skeletal development, MMP2 is integral to , where it contributes to remodeling and vascular invasion within the hypertrophic zone of growth plates, allowing maturation necessary for elongation. MMP2 deficiency in mouse models leads to disrupted remodeling, resulting in growth retardation, reduced mineralization, and phenotypes resembling , such as craniofacial dysmorphism and joint abnormalities. These defects highlight MMP2's specific function in and its non-redundant role alongside other gelatinases like MMP9 during longitudinal growth. MMP2 contributes to by promoting endothelial cell invasion into the perivascular matrix during vessel sprouting. It specifically cleaves in basement membranes, creating pathways for endothelial tip cells to extend and form new vascular branches. This proteolytic activity is crucial for the directional migration of endothelial cells through dense ECM, as evidenced by impaired angiogenic responses in MMP2^{-/-} aortic ring assays. In lymphangiogenesis, MMP2 supports the formation of lymphatic vessels by remodeling the ECM surrounding lymphatic endothelial cells (LECs), particularly in response to C (VEGF-C) signaling. MMP2 acts as an , cleaving fibrillar to remodel the ECM, facilitating LEC migration and tube formation, as shown in MMP2^{-/-} models where dense ECM impedes lymphatic sprouting. Seminal studies from the , including the generation of MMP2 mice, revealed that these animals are viable but display impaired , with reduced vessel formation in developmental contexts due to defective ECM degradation. Subsequent conditional approaches have elucidated stage-specific roles, demonstrating that MMP2 is indispensable for early invasive processes like penetration while exerting regulatory effects on later ductal elongation in organ development.

Pathological Implications

Role in Cancer Progression

Matrix metalloproteinase-2 (MMP2), also known as gelatinase A, plays a pivotal pro-oncogenic role in cancer progression by remodeling the (ECM) and modulating cellular processes that favor tumor growth and dissemination. Overexpression of MMP2 is commonly observed in various solid tumors, where it contributes to the degradation of ECM barriers, thereby facilitating key steps in . MMP2 facilitates cancer cell invasion primarily through its degradation of , a major component of the that separates epithelial tissues from the underlying stroma. This proteolytic activity enables epithelial-mesenchymal transition (EMT), a process where cancer cells acquire migratory and invasive properties, as demonstrated in , colon, and cancers. By cleaving ECM proteins, MMP2 not only disrupts physical barriers but also creates pathways for tumor cells to infiltrate surrounding tissues. In promoting , MMP2 enhances intravasation and of cancer cells at primary and secondary sites, with elevated levels detected in a majority of invasive carcinomas. This supports the metastatic cascade by degrading matrices, allowing tumor cells to enter the bloodstream and establish distant lesions. Interactions with tissue inhibitors of metalloproteinases (TIMPs) in the tumor stroma can modulate MMP2 activity, influencing metastatic potential. MMP2 contributes to the angiogenic switch in tumors by cleaving ECM components such as , which releases bound pro-angiogenic factors including (VEGF) and (FGF). This process promotes endothelial and tube formation, correlating with increased microvessel density in various cancers. Additionally, MMP2 modulates pathways by processing latent growth factors, such as releasing active TGF-β from its latency-associated peptide, and cleaving ligands for receptors like EGFR, thereby enhancing tumor cell survival and proliferation. High MMP2 expression serves as a prognostic indicator, associating with poor overall survival in gliomas and melanomas. Furthermore, elevated serum levels of MMP2 have been detected in patients with advanced malignancies, positioning it as a potential circulating for monitoring disease progression.

Involvement in Chronic Diseases

Matrix metalloproteinase-2 (MMP2) plays a significant role in various chronic diseases characterized by dysregulated extracellular matrix (ECM) remodeling, , and , leading to progressive tissue damage outside of neoplastic contexts. In these conditions, MMP2's proteolytic activity often contributes to pathological degradation of structural proteins, exacerbating disease progression through mechanisms such as vascular instability and fibrotic accumulation. In , MMP2 degrades and within the arterial wall, promoting plaque instability and increasing the risk of rupture. This activity is upregulated in macrophages by oxidized (oxLDL), which enhances MMP2 expression and contributes to the inflammatory remodeling of atherosclerotic lesions. Elevated MMP2 levels in patients further underscore its involvement in plaque vulnerability and cardiovascular complications. MMP2 is implicated in (RA) by facilitating synovial and erosion through ECM breakdown in joint tissues. Levels of MMP2 in RA synovial fluid correlate positively with the extent of joint destruction, reflecting its contribution to chronic synovial inflammation and tissue degradation. Studies of endogenous MMP2 in RA models demonstrate its promotion of migration and , amplifying arthritic pathology. In (CKD), MMP2 participates in tubulointerstitial by degrading ECM components and activating transforming growth factor-β (TGF-β), which drives excessive collagen deposition and renal scarring. This process is particularly evident in models, where elevated MMP2 expression predicts progression and glomerular damage. Deficient regulation of MMP2 can lead to disruption, accelerating the transition from early CKD to advanced fibrotic stages. Excessive MMP2 activity weakens vessel walls in (AAA) by proteolyzing and , thereby promoting aneurysmal dilation and rupture risk. Polymorphisms in the MMP2 gene, such as the -1306C/T variant in the promoter region, which can influence its expression levels in vascular smooth muscle cells, have been investigated in relation to AAA susceptibility. Ubiquitous elevation of MMP2 in aneurysmal tissues supports its central role in ECM instability during AAA pathogenesis. MMP2 has context-dependent links to neurodegenerative diseases, including degradation of in (MS) and involvement in amyloid-β (Aβ) processing in (AD). In MS, MMP2 contributes to myelin breakdown by reactive , facilitating demyelination during inflammatory episodes, though its exact role varies with disease stage. In AD, MMP2 aids in the physiological degradation of extracellular Aβ peptides, but dysregulated activity may alter Aβ clearance, potentially influencing plaque formation in early pathology.

Therapeutic and Clinical Aspects

Inhibitors and Drug Development

Natural inhibitors of MMP2 primarily include the tissue inhibitors of metalloproteinases (TIMPs), with TIMP-1 and TIMP-2 forming tight 1:1 complexes by binding to the enzyme's , exhibiting inhibition constants (Ki) in the range of approximately 10^{-9} M. TIMP-2 specifically interacts with the proenzyme form of MMP2 to regulate its activation on cell surfaces, while both TIMPs broadly suppress MMP activity in extracellular matrices. Additionally, α2-macroglobulin acts as a broad-spectrum physiological trap, capturing active MMP2 and other proteases through covalent binding, thereby facilitating their clearance from circulation. Early synthetic inhibitors targeted the in the MMP2 catalytic site using hydroxamate-based chelators, with broad-spectrum agents like batimastat and marimastat showing preclinical promise in blocking tumor invasion but failing in Phase III clinical trials during the and . These failures were attributed to dose-limiting musculoskeletal toxicity, including and tendonitis, stemming from off-target inhibition of non-oncogenic MMPs essential for tissue , as well as insufficient efficacy due to poor selectivity. Efforts to develop more selective MMP2 inhibitors, such as tanomastat and prinomastat, focused on gelatinases like MMP2 and MMP9 to enhance specificity, but clinical trials in cancer patients revealed limited therapeutic benefits. For instance, a 2002 Phase III trial of tanomastat in was halted early due to inefficacy compared to standard , while prinomastat showed no survival advantage in non-small cell studies despite targeting MMP2, MMP3, MMP9, MMP13, and MMP14. Emerging therapeutic strategies include monoclonal antibodies targeting gelatinases, such as GS-5745 (andecaliximab) against MMP9, currently under evaluation in and inflammatory trials for improved tolerability over small molecules. Peptide-based inhibitors, including cyclic peptides like CTT, have demonstrated selective MMP2 blockade in preclinical models by disrupting enzyme-substrate interactions or activation, offering advantages in tissue permeability and reduced toxicity. approaches, such as siRNA-mediated silencing of MMP2, have shown efficacy in reducing tumor invasion and matrix degradation and in animal models of cancer and , with delivery systems enhancing specificity. Key challenges in MMP2 inhibitor development persist, including off-target effects on homologous MMP family members that contribute to side effects like , necessitating higher selectivity. Tumor-specific delivery remains critical to mitigate systemic , with nanoparticle-based systems—such as MMP2-responsive micelles—emerging to enable localized release and improve in preclinical cancer models.

Biomarker Applications

Matrix metalloproteinase-2 (MMP2) serves as a valuable biomarker in various clinical contexts, particularly for detecting and monitoring disease progression in oncology and cardiovascular conditions. In serum and plasma, pro-MMP2 levels are commonly measured using enzyme-linked immunosorbent assay (ELISA), indicating potential tumor invasion and metastasis in cancers such as colorectal and breast carcinoma. For assessing active MMP2 forms, gelatin zymography is employed on tissue extracts, revealing increased enzymatic activity in malignant tissues compared to normal counterparts, as seen in colorectal cancer where active MMP2 is detectable in nearly all cases. Tissue-based evaluation through immunohistochemistry (IHC) demonstrates strong MMP2 expression correlating with higher tumor grades in invasive ductal of the breast, where intense staining is present in up to 75% of cases, particularly in grades 2 and 3 tumors. Additionally, urinary MMP2 levels serve as a non-invasive marker for monitoring, with elevated concentrations distinguishing low- from high-grade tumors and aiding in recurrence detection. Prognostically, elevated MMP2 levels in serum or tissue predict increased risk and poorer survival outcomes; for instance, in gastric cancer, high MMP2 expression is associated with reduced overall survival, with meta-analyses confirming its role as an independent indicator of adverse prognosis. In imaging applications, MMP2-targeted probes enhance (MRI) sensitivity for detection by visualizing matrix remodeling in abdominal aortic walls. Circulating MMP2 also acts as a cardiovascular risk marker following (MI), where post-MI elevations correlate with adverse ventricular remodeling and increased incidence. Despite these utilities, MMP2 applications face limitations, including non-specificity due to elevations in inflammatory conditions unrelated to , which can confound diagnostic accuracy. Standardization challenges across assays persist, as variations in kits and zymography protocols affect reproducibility. Recent studies from the 2020s have explored integrating MMP2 measurements with (miRNA) profiles, such as miR-29b, to improve specificity by accounting for regulatory interactions in cancer progression.

Protein Interactions

Binding Partners and Regulation

Matrix metalloproteinase 2 (MMP2) interacts with several endogenous regulators that modulate its activity. The tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP-2, form a high-affinity complex with pro-MMP2, with a (Kd) of approximately 5 nM, facilitating its localization and inhibiting active MMP2. RECK, a membrane-anchored , acts as an endogenous inhibitor by directly suppressing MMP2 enzymatic activity, thereby regulating degradation. MMP2 also binds to various cell surface anchors that localize its activity. αvβ3 interacts with the domain of MMP2, enabling focalized at specific cellular sites such as invadopodia. Additionally, and tetraspanins like CD151 contribute to MMP2 recruitment and stabilization in invadopodia, enhancing its pericellular localization through associations with complexes. Substrate interactions further influence MMP2 function. (LDL), particularly in its oxidized form, interacts with MMP2 to enhance its activity in atherosclerotic lesions, promoting plaque instability. MMP2 binds types I and IV via its three tandem type II modules in the catalytic domain, which serve as a specific collagen-binding site essential for substrate recognition and degradation. Allosteric modulators affect MMP2 structure and activity. Calcium ions bind within the hemopexin domain, stabilizing its four-bladed β-propeller fold and maintaining overall protein integrity. Shifts in , such as those occurring in the acidic microenvironment of hypoxic tumors, alter MMP2 enzymatic activity, often enhancing its proteolytic efficiency under low-oxygen conditions. In the bloodstream, apolipoprotein A-I (APOA1) binds active MMP2 with high affinity (nanomolar Kd), protecting it from autoproteolysis and facilitating its transport and regulation. Genetic regulation of MMP2 involves promoter polymorphisms that impact binding and expression. The -735C/T variant in the MMP2 promoter modifies the affinity for transcription factors like Sp1, leading to altered levels associated with disease susceptibility. Activation of pro-MMP2 can involve transient interaction with MT1-MMP as a binding partner on the cell surface.

Functional Complexes

MMP2 participates in multi-component assemblies that localize its proteolytic activity to specific cellular structures, enabling targeted degradation of the (ECM) during processes such as and migration. These functional complexes integrate MMP2 with regulatory proteins, receptors, and signaling molecules, ensuring spatiotemporal control of its function and preventing uncontrolled . Seminal studies have identified key assemblies involving pro-MMP2, highlighting their role in concentrating enzymatic activity at sites of ECM remodeling. A prominent example is the cell surface trimolecular complex formed by pro-, tissue inhibitor of metalloproteinases-2 (TIMP-2), and membrane type 1 (MT1-) on invadopodia of invasive cells. In this assembly, TIMP-2 binds to the of MT1-, serving as a receptor that captures pro- via its domain, positioning it for activation by an adjacent free MT1- molecule. This complex concentrates activity at protrusive structures like invadopodia, facilitating pericellular matrix degradation essential for cell invasion in tumor microenvironments. The formation of this unit has been shown to be critical for efficient pro- processing and subsequent ECM in cells. In migrating cells, MMP2 integrates into ECM-receptor complexes, such as clusters involving (e.g., αvβ3) and , which link to intracellular signaling pathways. These assemblies form at the of migrating cells, where and co-localize to bind hyaluronan and ECM ligands, recruiting MMP2 to degrade barriers while activating focal adhesion (FAK). FAK in this context promotes cytoskeletal reorganization and directed migration, as observed in cells where osteopontin-induced signaling upregulates and MMP2 secretion. This clustering enhances cell motility by coupling ECM turnover to mechanosignaling, with disruptions impairing invasive potential. MMP2 also forms protective complexes in inflammatory contexts, notably associating with gelatinase-associated lipocalin (NGAL) within granules. This interaction shields MMP2 from autolytic degradation, stabilizing its activity for rapid release during acute inflammation. Although primarily studied for MMP9, NGAL's binding to MMP2 in cardiac and vascular tissues extends this protective role, preserving enzymatic function amid proteolytic environments. Such complexes enable sustained matrix remodeling in inflammatory responses without premature inactivation. In angiogenic processes, MMP2 contributes to assemblies involving receptor 2 (VEGFR2) and ECM-bound VEGF, particularly at endothelial tip cell protrusions. These interactions facilitate vessel sprouting by allowing MMP2 to process ECM components, releasing bioactive VEGF that binds VEGFR2 to drive extension and migration. In models, MMP2 modulates VEGF expression via integrin-mediated signaling, enhancing VEGFR2 activation and angiogenic responses in tip cells. This localized complex supports directed vascular outgrowth while integrating proteolytic and signaling. Therapeutically, disrupting these MMP2-containing complexes offers indirect inhibition strategies in preclinical models. For instance, anti-CD44 antibodies block the formation of CD44-integrin-MMP2 clusters, reducing MMP2-dependent migration and in cancer cells by preventing HA-mediated signaling and secretion. In hyaluronan-stimulated tumor lines, such antibodies inhibit MMP2 activation and ECM degradation, demonstrating reduced tumor progression in xenograft models. This approach highlights the potential of targeting complex assembly over direct enzymatic inhibition to mitigate MMP2's pathological roles.

References

  1. https://www.ncbi.nlm.nih.gov/gene/4313
  2. https://www.ncbi.nlm.nih.gov/omim/120360
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/
  4. https://www.mdpi.com/1422-0067/25/24/13691
  5. https://publications.ersnet.org/content/erj/38/1/191
  6. https://pubmed.ncbi.nlm.nih.gov/19182722/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10348858/
  8. https://pubmed.ncbi.nlm.nih.gov/39769454/
  9. https://www.proteinatlas.org/ENSG00000087245-MMP2/tissue
  10. https://www.informatics.jax.org/allele/MGI:2386252
  11. https://www.uniprot.org/uniprotkb/P08253/entry
  12. https://faseb.onlinelibrary.wiley.com/doi/10.1096/fasebj.12.12.1075
  13. https://www.pnas.org/doi/10.1073/pnas.102185399
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3190879/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4888457/
  16. https://pubmed.ncbi.nlm.nih.gov/24616914/
  17. https://www.ahajournals.org/doi/10.1161/01.res.0000070112.80711.3d
  18. https://www.cell.com/structure/fulltext/S0969-2126%2800%2980057-X
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3391158/
  20. https://pubmed.ncbi.nlm.nih.gov/7890717/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6747341/
  22. https://pubmed.ncbi.nlm.nih.gov/2269296/
  23. https://www.jbc.org/article/S0021-9258(20)87566-8/fulltext
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3004722/
  25. https://doi.org/10.1073/pnas.87.14.5578
  26. https://doi.org/10.1016/j.matbio.2007.07.001
  27. https://doi.org/10.1074/jbc.270.10.5331
  28. https://doi.org/10.1042/bj3040263
  29. https://doi.org/10.1074/jbc.M006871200
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10282173/
  31. https://www.liebertpub.com/doi/10.1089/wound.2014.0581
  32. https://www.jidonline.org/article/S0022-202X%2815%2940514-7/pdf
  33. https://article.imrpress.com/bri/Landmark/articles/pdf/Landmark1533.pdf
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC5029434/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10706207/
  36. https://www.dovepress.com/matrix-metalloproteinases--in-bone-development-and-pathology-current-k-peer-reviewed-fulltext-article-MNM
  37. https://journals.biologists.com/dmm/article/4/2/203/53511/Impaired-remodeling-phase-of-fracture-repair-in
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC10548276/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3594863/
  40. https://pubmed.ncbi.nlm.nih.gov/32344273/
  41. https://www.sciencedirect.com/science/article/abs/pii/S0165037807000344
  42. https://academic.oup.com/hmg/article/16/9/1113/688458
  43. https://www.sciencedirect.com/science/article/abs/pii/S0945053X2200124X
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6915110/
  45. https://www.ahajournals.org/doi/10.1161/01.res.0000260801.12916.b5
  46. https://ashpublications.org/blood/article-abstract/119/21/5048/29950
  47. https://www.pnas.org/doi/10.1073/pnas.060037197
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC2172848/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3506216/
  50. https://www.degruyterbrill.com/document/doi/10.1515/oncologie-2023-0368/html
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC2886087/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9557123/
  53. https://www.sciencedirect.com/science/article/pii/S1040842818304876
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4474140/
  55. https://www.nature.com/articles/s41392-021-00544-0
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC5765875/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC3918721/
  58. https://www.sciencedirect.com/science/article/pii/S0092867410002886
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6958083/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC9930295/
  61. https://www.sciencedirect.com/science/article/pii/S0753332219316671
  62. https://pubmed.ncbi.nlm.nih.gov/37457745/
  63. https://pubmed.ncbi.nlm.nih.gov/24517161/
  64. https://academic.oup.com/rheumatology/article/53/12/2270/1803683
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC4097284/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9482425/
  67. https://www.imrpress.com/journal/FBL/29/5/10.31083/j.fbl2905192/htm
  68. https://pubmed.ncbi.nlm.nih.gov/19515587/
  69. https://www.ahajournals.org/doi/10.1161/01.cir.104.3.304
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4950938/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC4463451/
  72. https://www.jneurosci.org/content/26/43/10939
  73. https://www.nature.com/articles/s41598-017-05039-z
  74. https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2010.07920.x
  75. https://journals.biologists.com/jcs/article/115/19/3719/26779/Metalloproteinase-inhibitors-biological-actions
  76. https://www.nature.com/articles/nrd4390
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC7277161/
  78. https://aacrjournals.org/mct/article/17/6/1147/92406/Matrix-Metalloproteinase-Inhibitors-in-Cancer
  79. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14186
  80. https://www.ahajournals.org/doi/10.1161/01.res.87.8.670
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC10007186/
  82. https://pubs.acs.org/doi/10.1021/acs.biomac.3c00421
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC2773480/
  84. https://aacrjournals.org/cebp/article/21/8/1371/69287/Preoperative-Serum-Levels-of-Matrix
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC2775048/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC10861259/
  87. https://pubmed.ncbi.nlm.nih.gov/22030137/
  88. https://www.sciencedirect.com/science/article/abs/pii/S0344033811002159
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC4580016/
  90. https://www.sciencedirect.com/science/article/abs/pii/S0302283807004757
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC2361233/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC11823695/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC2908304/
  94. https://www.sciencedirect.com/science/article/abs/pii/S1549963420300290
  95. https://www.ahajournals.org/doi/10.1161/hh1501.094396
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC5576003/
  97. https://www.tandfonline.com/doi/full/10.2144/05381RV01
  98. https://jmhg.springeropen.com/articles/10.1186/s43042-023-00434-w
  99. https://pubmed.ncbi.nlm.nih.gov/9368077/
  100. https://www.sciencedirect.com/science/article/pii/S0092867401005979
  101. https://www.pnas.org/doi/10.1073/pnas.98.1.119
  102. https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2010.07918.x
  103. https://www.molbiolcell.org/doi/10.1091/mbc.e08-11-1149
  104. https://www.ahajournals.org/doi/10.1161/01.cir.0000136995.83451.1d
  105. https://www.jbc.org/article/S0021-9258%2820%2977089-4/pdf
  106. https://www.explorationpub.com/Journals/etat/Article/10025
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC12015353/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC2148054/
  109. https://www.nature.com/articles/cr199818
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/
  111. https://www.nature.com/articles/6603863
  112. https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1003086
  113. https://www.sciencedirect.com/science/article/abs/pii/S0014482706001157
  114. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2018.00097/full
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC126155/
  116. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.115.05479
  117. https://www.sciencedirect.com/science/article/abs/pii/S0959804907004017
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC2891576/
  119. https://academic.oup.com/cardiovascres/article/78/2/203/348899
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC2909682/
  121. https://www.researchgate.net/figure/Expression-of-CD44-and-HA-dependent-MMP-2-secretion-in-various-human-cancer-cell-lines_fig1_11255336
Add your contribution
Related Hubs
User Avatar
No comments yet.